- Home
- TSVT
TSVT
2seventy bio Inc.
as 01-21-2025 4:00pm EST
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
| Founded: | 2021 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 128.5M | IPO Year: | N/A |
| Target Price: | $10.40 | AVG Volume (30 days): | 449.7K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.35 - $6.40 | Next Earning Date: | 03-04-2025 |
| Revenue: | $45,620,000 | Revenue Growth: | -68.73% |
| Revenue Growth (this year): | -51.01% | Revenue Growth (next year): | 36.09% |
Stock Insider Trading Activity of 2seventy bio Inc. (TSVT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Baird William D III | TSVT | President and CEO | Jan 3 '25 | Sell | $2.86 | 32,481 | $95,240.87 | 862,889 | |
| Leschly Nick | TSVT | Director | Jan 3 '25 | Sell | $2.86 | 86,870 | $254,901.23 | 1,234,498 | |
| Eatwell Victoria | TSVT | Chief Financial Officer | Jan 3 '25 | Sell | $2.86 | 1,110 | $3,243.58 | 339,076 | |
| Snow Jessica | TSVT | See Remarks | Dec 13 '24 | Sell | $3.23 | 2,287 | $7,393.41 | 153,479 | |
| Maus Marcela V. | TSVT | Director | Nov 18 '24 | Sell | $3.38 | 3,900 | $13,182.39 | 23,752 |
Latest 2seventy bio Inc. News
TSVT Breaking Stock News: Dive into TSVT Ticker-Specific Updates for Smart Investing
Simply Wall St.
21 hours ago
US Penny Stocks Spotlight: uCloudlink Group Among 3 Noteworthy Picks
Simply Wall St.
a month ago
US Penny Stocks To Watch In December 2024
Simply Wall St.
2 months ago
US$8.25: That's What Analysts Think 2seventy bio, Inc. (NASDAQ:TSVT) Is Worth After Its Latest Results
Simply Wall St.
2 months ago
2seventy bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Business Wire
2 months ago
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
Simply Wall St.
2 months ago
3 Promising US Penny Stocks With At Least $100M Market Cap
Business Wire
3 months ago
2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference
Simply Wall St.
3 months ago
High Growth Tech Stocks To Watch In October 2024
Compare TSVT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TSVT 2seventy bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.